PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1424465
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1424465
The global clinical nutrition market size was valued at US$ 11.10 Bn in 2023 and is expected to reach US$ 16.48 Bn by 2030, growing at a Compound Annual Growth Rate (CAGR) of 5.8% from 2023 to 2030.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2022 | Market Size in 2023/2024: | US$ 11.10 Bn |
Historical Data for: | 2017 to 2021 | Forecast Period: | 2023 - 2030 |
Forecast Period 2023/2024 to 2030/2031 CAGR: | 5.80% | 2030/2031 Value Projection: | US$ 16.48 Bn |
Clinical nutrition refers to the specialized nutrition support provided to patients who are acutely ill and malnourished or have specific medical conditions requiring modifications to their usual diet. It involves the assessment, diagnosis, intervention, and monitoring of patients' nutritional needs. Clinical nutrition enables the management of various conditions like cancer, neurological disorders, gastrointestinal diseases, wounds, or injuries that impact dietary intake and nutrient absorption. It plays a vital role in reducing disease complications, supporting healing processes, and improving treatment outcomes and recovery times of patients. The widespread prevalence of chronic diseases and rising elderly population worldwide have increased the demand for specialized clinical nutrition over the past decade.
The growth of the global clinical nutrition market is driven by the rising geriatric population, increasing prevalence of chronic and lifestyle diseases, growing demand for nutritional products in homecare and healthcare settings, and the launch of research and development facilities for infant nutrition. However, factors like limited awareness regarding clinical nutrition therapy and stringent regulatory framework are restraining the market growth. The development of personalized nutritional products based on an individual's genetic profile is paving opportunities for market players. Also, growing research on using enteral and parenteral nutrition in new therapeutic areas like oncology and neurology presents a lucrative outlook.
For instance, in October, Bobbie Baby, an organic infant formula company, announced the official launch of Bobbie Labs, its research and development hub, dedicated to infant feeding. Bobbie Labs is a core element of the company's commitment to invest US$ 100 million to increase infant formula access, quality, and options for all U.S. families by 2030.